Tags

Type your tag names separated by a space and hit enter

c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Croat Med J. 2003 Aug; 44(4):429-34.CM

Abstract

AIM

To demonstrate immunohistochemical expression of p53, c-erbB-2, and nm23 proteins in ovarian cancer and to establish their correlation with such predictive factors as clinical stage, grade, and vascular invasion. The effect of protein overexpression on patients' overall survival was also assessed.

METHOD

We performed immunohistochemical analysis of formalin-fixed, paraffin-embedded specimens from 80 ovarian carcinomas, using the anti-nm23, p53, and c-erbB-2 monoclonal antibodies. Immunohistochemical results were scored semiquantitatively. All patients were staged according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO) staging system (I-IV). Carcinomas were graded as low- or high-grade, according to the modified grading system recommended by Shimatzu and Silverberg. For univariate analysis, survival time was analyzed by Kaplan-Meier method, and the log-rank test was used to assess the differences between the groups. For multivariate analysis, Cox proportional hazard regression model was used to examine several parameters simultaneously.

RESULTS

Univariate analysis showed that advanced clinical stage (p<0.001); positive staining for nm23 (p<0.001), p53 (p=0.021), and c-erbB-2 (p=0.003) protein; high histological grade (p<0.001); and vascular invasion (p=0.006) were associated with shorter overall survival. Multivariate analysis revealed only clinical stage as an independent prognostic parameter (p=0.014). Multivariate analysis for early-stage disease showed that only the presence of vascular invasion was significantly associated with shorter survival (p=0.008), whereas none of the parameters analyzed for the advanced-stage disease showed independent predictive value for prognosis.

CONCLUSION

The overexpression of p53, nm23, and c-erbB-2 proteins was associated with other parameters characteristic of aggressive tumors, such as advanced clinical stage, high grade, and/or presence of vascular invasion. However, this overexpression had no independent prognostic value either for overall survival or survival corrected by clinical stages.

Authors+Show Affiliations

Department of Pathology, Split University Hospital Center and School of Medicine, Croatia. snjezana.tomic@st.hinet.hrNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

12950146

Citation

Tomić, Snjezana, et al. "C-erbB-2, P53, and Nm23 Proteins as Prognostic Factors in Patients With Epithelial Ovarian Carcinoma." Croatian Medical Journal, vol. 44, no. 4, 2003, pp. 429-34.
Tomić S, Ilić Forko J, Babić D, et al. C-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Croat Med J. 2003;44(4):429-34.
Tomić, S., Ilić Forko, J., Babić, D., Sundov, D., Kuret, S., & Andelinović, S. (2003). C-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Croatian Medical Journal, 44(4), 429-34.
Tomić S, et al. C-erbB-2, P53, and Nm23 Proteins as Prognostic Factors in Patients With Epithelial Ovarian Carcinoma. Croat Med J. 2003;44(4):429-34. PubMed PMID: 12950146.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. AU - Tomić,Snjezana, AU - Ilić Forko,Jadranka, AU - Babić,Damir, AU - Sundov,Dinka, AU - Kuret,Sendi, AU - Andelinović,Simun, PY - 2003/9/2/pubmed PY - 2003/10/24/medline PY - 2003/9/2/entrez SP - 429 EP - 34 JF - Croatian medical journal JO - Croat Med J VL - 44 IS - 4 N2 - AIM: To demonstrate immunohistochemical expression of p53, c-erbB-2, and nm23 proteins in ovarian cancer and to establish their correlation with such predictive factors as clinical stage, grade, and vascular invasion. The effect of protein overexpression on patients' overall survival was also assessed. METHOD: We performed immunohistochemical analysis of formalin-fixed, paraffin-embedded specimens from 80 ovarian carcinomas, using the anti-nm23, p53, and c-erbB-2 monoclonal antibodies. Immunohistochemical results were scored semiquantitatively. All patients were staged according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO) staging system (I-IV). Carcinomas were graded as low- or high-grade, according to the modified grading system recommended by Shimatzu and Silverberg. For univariate analysis, survival time was analyzed by Kaplan-Meier method, and the log-rank test was used to assess the differences between the groups. For multivariate analysis, Cox proportional hazard regression model was used to examine several parameters simultaneously. RESULTS: Univariate analysis showed that advanced clinical stage (p<0.001); positive staining for nm23 (p<0.001), p53 (p=0.021), and c-erbB-2 (p=0.003) protein; high histological grade (p<0.001); and vascular invasion (p=0.006) were associated with shorter overall survival. Multivariate analysis revealed only clinical stage as an independent prognostic parameter (p=0.014). Multivariate analysis for early-stage disease showed that only the presence of vascular invasion was significantly associated with shorter survival (p=0.008), whereas none of the parameters analyzed for the advanced-stage disease showed independent predictive value for prognosis. CONCLUSION: The overexpression of p53, nm23, and c-erbB-2 proteins was associated with other parameters characteristic of aggressive tumors, such as advanced clinical stage, high grade, and/or presence of vascular invasion. However, this overexpression had no independent prognostic value either for overall survival or survival corrected by clinical stages. SN - 0353-9504 UR - https://www.unboundmedicine.com/medline/citation/12950146/c_erbB_2_p53_and_nm23_proteins_as_prognostic_factors_in_patients_with_epithelial_ovarian_carcinoma_ DB - PRIME DP - Unbound Medicine ER -